DexCom’s fair value price target has been tweaked from US$85.85 to US$86.12 per share, a small shift that still matters if ...

Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong fourth-quarter 2025 ...

If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult ...

Opportunities include integrating digital health for remote care, leveraging demographic trends, and overcoming CGM unit costs to expand access across regionsDublin, March 16, 2026 (GLOBE NEWSWIRE) -- ...

Researchers have found in a new study that continuous glucose monitoring (CGM) in the ICU appears to provide reliable glucose ...

(NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose ...

Without a specific news headline driving the move, DexCom (DXCM) sits at a recent close of US$70.69, leaving investors weighing its continuous glucose monitoring business against recent share price ...

In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...